Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Ranbaxy Calls Rudy Giuliani for Help

Posted by: Bruce Einhorn on September 18, 2008

We’ve been covering the ongoing problems that Indian drugmaker Ranbaxy has been having with the FDA in the U.S. Now, just days after the FDA announced a ban on the import of over two dozen of its drugs, Ranbaxy has unveiled its latest tactic: The company is betting Rudy Giuliani can help solve its problems. Ranbaxy announced today that it has hired Giuliani Partners “to provide advice and review compliance issues related to the recent United States Food and Drug Administration letters and Import Advisory.”

This seems like a pretty risky move. Yes, should McCain win the election, having Rudy on board could very well help Ranbaxy deal with the regulators. But what does Ranbaxy do if Obama wins? Or maybe the company is planning on the whole thing getting resolved before the new president – McCain or Obama – takes office in Jan. 20.

In related Ranbaxy news, my colleague Mehul Srivastava in Delhi notes that we should be keeping an eye on the stock price tomorrow. As Mehul points out, the trading volume on Ranbaxy stock was surprisingly thin yesterday after the FDA announcement, especially when compared to the 10% drop earlier this summer following news that the FDA was investigating the company. Turns out a lot of the shares are caught up in the open offer to Daiichi Sankyu, the Japanese drugmaker that is in the process of taking over Ranbaxy, and are thus not available for trading. “But on the 19th-20th, Daiichi will refund/credit the shares that it did not buy (the offer was oversubsribed),” Mehul writes, “and unless there’s good news, folks likely will sell them.”

Reader Comments


September 19, 2008 11:15 PM

India is the only country in world that still suffers plague and has most Aids infected people. Indians urinate and defecates everywhere, on the streets, under the trees and in the river and grab foods and wipe wastes using bare fingers. It is simply scary to have any medicine made at such places!


September 20, 2008 10:16 AM

I would think that there are technical guidelines that the FDA expects Ranbaxy to meet or exceed. This article makes it seems political without detail why 2 dozen drugs were rejected.

Jalal Alamgir

September 22, 2008 11:29 PM

The US FDA's rejection of Ranbaxy drugs has next to nothing to do with US elections. The hiring of a well-connected consulting firm to advise on the matter simply exposes rational management decision.

Jalal Alamgir


September 25, 2008 8:18 PM

Dear nickn,

US imported medicines from the same India following anthrax scare? Was it ok then? because it was 99% cheaper?

Post a comment



Bloomberg Businessweek’s team of Asia reporters brings you the latest insights on business, politics, technology and culture from some of the world’s biggest and fastest-growing economies.

BW Mall - Sponsored Links

Buy a link now!